---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-046976"
form_type: "8-K"
ticker: null
cik: "0001267813"
company_name: "MARINUS PHARMACEUTICALS, INC."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:49:27.879807+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Marinus RAISE trial interim analysis fails early stopping criteria; Q1 ZTALMY revenue $7.4-7.6M

## Summary
- DMC recommended continue RAISE; enrollment completed at ~100 patients; topline results summer 2024.
- Q1 2024 preliminary ZTALMY net revenue $7.4-7.6 million; cash $113.3 million as of March 31.
- TrustTSC enrollment expected mid-May; topline data on track for Q4 2024.
- Cost reduction activities under review to extend cash runway beyond Q4 2024.
- IV ganaxolone development for RSE to be reassessed after final RAISE results.

## SEC filing metadata
- accession: 0001104659-24-046976
- form_type: 8-K
- cik: 0001267813
- company_name: MARINUS PHARMACEUTICALS, INC.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/0001104659-24-046976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/tm2411822d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-046976
- JSON: https://secwatch.observer/filing/0001104659-24-046976.json
- Plain text: https://secwatch.observer/filing/0001104659-24-046976.txt

## Key facts
- Earnings Releases
  MARINUS PHARMACEUTICALS, INC. reported the quarter ended March 31, 2024 results: revenue between $7.4 and $7.6 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: between $7.4 and $7.6 million
  - Result: preliminary results
  source text: Cost reduction activities to extend cash runway are under review and expected to be implemented Q2 2024 ZTALMY ® (ganaxolone) Q1 2024 preliminary net product revenue of between $7.4 and $7.6 million; preliminary unaudited cash, cash equivalents and short-term investments of $113.3 million as of March 31, 2024 RADNOR, Pa. – April 15, 2024 – Marinus
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267813/000110465924046976/0001104659-24-046976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.